Axim Biotechnologies Financials
| AXIM Stock | USD 0 0 50.00% |
Axim |
Understanding current and past Axim Biotechnologies Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Axim Biotechnologies' financial statements are interrelated, with each one affecting the others. For example, an increase in Axim Biotechnologies' assets may result in an increase in income on the income statement.
Axim Biotechnologies Stock Summary
Axim Biotechnologies competes with Cellectis, Ascletis Pharma, and GH Research. AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California. Axim Biotechnologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 6 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US05463V1008 |
| Business Address | 6191 Cornerstone Court, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.aximbiotech.com |
| Phone | 858 923 4422 |
| Currency | USD - US Dollar |
Axim Biotechnologies Key Financial Ratios
There are many critical financial ratios that Axim Biotechnologies' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Axim Biotechnologies reports annually and quarterly.| Return On Equity | -100.19 | |||
| Return On Asset | -0.35 | |||
| Beta | 1.49 | |||
| Z Score | -15.0 |
Axim Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Axim Biotechnologies's current stock value. Our valuation model uses many indicators to compare Axim Biotechnologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Axim Biotechnologies competition to find correlations between indicators driving Axim Biotechnologies's intrinsic value. More Info.Axim Biotechnologies is rated fourth in return on equity category among its peers. It is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Axim Biotechnologies' earnings, one of the primary drivers of an investment's value.Axim Biotechnologies Systematic Risk
Axim Biotechnologies' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Axim Biotechnologies volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Axim Biotechnologies correlated with the market. If Beta is less than 0 Axim Biotechnologies generally moves in the opposite direction as compared to the market. If Axim Biotechnologies Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Axim Biotechnologies is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Axim Biotechnologies is generally in the same direction as the market. If Beta > 1 Axim Biotechnologies moves generally in the same direction as, but more than the movement of the benchmark.
Axim Biotechnologies December 3, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Axim Biotechnologies help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Axim Biotechnologies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Axim Biotechnologies based on widely used predictive technical indicators. In general, we focus on analyzing Axim Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Axim Biotechnologies's daily price indicators and compare them against related drivers.
| Downside Deviation | 25.16 | |||
| Information Ratio | 0.0128 | |||
| Maximum Drawdown | 133.33 | |||
| Value At Risk | (33.33) | |||
| Potential Upside | 33.33 |
Other Information on Investing in Axim Pink Sheet
Axim Biotechnologies financial ratios help investors to determine whether Axim Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axim with respect to the benefits of owning Axim Biotechnologies security.